CClinicalTrials.gg
Sign In
Status unknownNCT03478943Updated May 28, 2020

The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province

An observational study in Gastric Cancer, sponsored by Henan Cancer Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-28.

Sponsored by Henan Cancer Hospital · Observational

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .

02

Conditions studied

  • Gastric Cancer

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

patients of gastric cancer in Henan province

Inclusion criteria

  1. Male or female patients .
  2. Confirmed by Pathology or histology of Gastric cancer.
  3. Patients should be voluntary to the trial and provide with signed informed consent.
  4. The researchers believe patients can benefit from the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories.
  2. Pregnant or lactating women.
  3. Patients with Apatinib contraindications.
  4. Patients of doctors considered unsuitable for the trial.
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Progress free survival

    Time frame: 1 year

  2. Disease-free surviva

    Time frame: 1 year

Secondary outcomes

  1. overall survival

    Time frame: 3 year

  2. Objective Response Rate

    Time frame: 1 year

  3. Disease Control Rate

    Time frame: 1 year

06

Study locations

1 site
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
07

Registry details

Key details

Study ID
NCT03478943
Lead sponsor
Henan Cancer Hospital
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
Jan 30, 2016
Primary completion
Aug 1, 2020 (estimated)
Completion
Dec 1, 2020 (estimated)
Last update
May 28, 2020

Study contacts

Suxia Luo
principal investigator · Henan Cancer Hospital
Peichun Sun
principal investigator · Henan Provincial People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Stomach Neoplasms→

Other studies from this sponsor

Henan Cancer Hospital

Start the discussion